RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/25604244http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25604244http://www.w3.org/2000/01/rdf-schema#comment"The chemotherapeutic agent cisplatin is widely used for treatment of head and neck squamous cell carcinoma (HNSCC). B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein that is overexpressed in cancer cells and confers resistance to cisplatin. Thus, inhibition of Bcl-2 expression may enhance the cisplatin sensitivity of cancer cells. In this study, we report that the AU-rich element (ARE) binding protein tristetraprolin (TTP) inhibits the expression of Bcl-2 and enhances cisplatin sensitivity of HNSCC cells. Cisplatin-sensitive HNSCC cells express high levels of TTP and low levels of Bcl-2, while cisplatin-resistant HNSCC cells have low levels of TTP and high levels of Bcl-2. Inhibition of TTP expression using siRNA increases levels of Bcl-2 and decreases cisplatin sensitivity in HNSCC cells. On the contrary, overexpression of TTP decreases Bcl-2 expression and increases sensitivity to cisplatin. Together, the results of the present study suggest that TTP expression enhances cisplatin sensitivity in HNSCC cells by reducing levels of Bcl-2."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.org/dc/terms/identifier"doi:10.1179/1973947814y.0000000234"xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Lee J.H."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Kim Y.H."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Lee B.J."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Park J.W."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Park S.B."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Cha H.J."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Cho W.J."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Do J.W."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Chung H.T."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Ko B.K."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Joe Y."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/author"Jeong W.W."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/name"J Chemother"xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/pages"174-180"xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/title"TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2."xsd:string
http://purl.uniprot.org/citations/25604244http://purl.uniprot.org/core/volume"27"xsd:string
http://purl.uniprot.org/citations/25604244http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/25604244
http://purl.uniprot.org/citations/25604244http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/25604244
http://purl.uniprot.org/uniprot/#_A0A1L4AQQ4-mappedCitation-25604244http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25604244
http://purl.uniprot.org/uniprot/#_P10415-mappedCitation-25604244http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25604244
http://purl.uniprot.org/uniprot/#_A0A1L4AQQ5-mappedCitation-25604244http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25604244